Summary
Inspiratory Muscle Training is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 2 registered trials linking Inspiratory Muscle Training to Long COVID: 2 have completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2022. The literature layer holds 19 publications for this pair: 3 systematic reviews, 8 clinical trial publications and 8 other publications. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 40.0 (trials 5.0, literature 30.0, tier 5, approved bonus 0.0) |
| Registered trials | 2 total: 0 recruiting, 0 active / not yet recruiting, 2 completed, 0 other |
| Linked publications | 19 (8 other publications, 8 clinical trial publications, 3 systematic reviews) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not recorded |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05196529 | Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors York University · 2022 | completed | Not applicable | 40 |
| NCT05279430 | Effects of IMT on Functional Capacity in Patients With Chronic COVID After Hospital Discharge Fundación para la Investigación del Hospital Clínico de Valencia · 2022 | completed | Not applicable | 26 |
Published literature
- Clinical trial publication (PubMed validation search) PubMed record PMID 42201014
- Clinical trial publication (PubMed validation search) PubMed record PMID 42012216
- Clinical trial publication (PubMed validation search) PubMed record PMID 41906071
- Clinical trial publication (PubMed validation search) PubMed record PMID 39374820
- Clinical trial publication (PubMed validation search) PubMed record PMID 38917451
- Clinical trial publication (PubMed validation search) PubMed record PMID 38763165
- Clinical trial publication (PubMed validation search) PubMed record PMID 38648998
- Clinical trial publication (PubMed validation search) PubMed record PMID 36549786
- Review (PubMed validation search) PubMed record PMID 42320154
- Review (PubMed validation search) PubMed record PMID 39658729
- Review (PubMed validation search) PubMed record PMID 37987274
- Review (PubMed validation search) PubMed record PMID 37841213
- Review (PubMed validation search) PubMed record PMID 36412084
- Case series (PubMed validation search) PubMed record PMID 38961771
- Case report (PubMed validation search) PubMed record PMID 39257640
- Case report (PubMed validation search) PubMed record PMID 37884259
- Systematic review (PubMed validation search) PubMed record PMID 41267122
- Systematic review (PubMed validation search) PubMed record PMID 41005678
- Systematic review (PubMed validation search) PubMed record PMID 39603702
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
Clinical notes: Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Inspiratory Muscle Training approved for Long COVID?
Inspiratory Muscle Training is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Inspiratory Muscle Training in clinical trials for Long COVID?
ClinicalTrials.gov lists 2 registered trials linking Inspiratory Muscle Training to Long COVID: 2 have completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2022.
What does the evidence show for Inspiratory Muscle Training in Long COVID?
Inspiratory Muscle Training has both completed registered trials and synthesis-level publications linked to Long COVID. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.